Redeye missed on sales and EBIT but was positively surprised by the strong gross margin. The quarter was affected by one-offs in OPEX, coupled with seasonality effects. However, we are encouraged by the strong and important activities carried out in and after the quarter, opting for Devyser to deliver impressively during 2024.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Devyser Diagnostics Q4 - Better positioned than ever

© Modular Finance, source Nordic Press Releases